Par Pharmaceutical Sued by Horizon Over Duexis Generic
Par Pharmaceutical Cos. was sued for patent infringement by Horizon Pharma Inc. (HNP) over a generic version of the drug Duexis, used to treat arthritis.
Horizon, based in Northbrook, Illinois, contends Par plans to market a copy of the drug before two U.S. patents expire in 2026, according to a complaint filed yesterday in federal court in Wilmington, Delaware.
Unless a judge stops the alleged infringement, “Horizon will be irreparably harmed,” the company said in court papers.
Gross sales for Duexis in the third quarter of 2012 were $3 million, Horizon said in a Nov. 13 statement.
Stephen Mock, a spokesman for Woodcliff Lake, New Jersey- based Par, didn’t immediately return a phone call seeking comment on the lawsuit.
The case is Horizon Pharma v. Par Pharmaceutical, U.S. District Court, District of Delaware (Wilmington).
To see the patents in the lawsuit, click: 8,309,127 and 8,318,202.
To contact the reporter on this story: Phil Milford at email@example.com.
To contact the editor responsible for this story: Michael Hytha at firstname.lastname@example.org
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.